enVVeno Medical Corporation (NVNO) 10-Year Financial Performance & Capital Metrics

NVNO • • Industrial / General

HealthcareMedical DevicesCardiovascular DevicesVascular & Aortic Devices

AboutenVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.Show more

Revenue $0
EBITDA -$23M +5.6%
Net Income -$22M +7.2%
EPS (Diluted) -1.27 +33.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -49.39% +10.8%
ROIC -41.82% +11.8%
Debt/Equity 0.03 -16.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 39.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM21.58%

ROCE

10Y Avg-364.56%

5Y Avg-84.15%

3Y Avg-54.15%

Latest-52.87%

Peer Comparison

Vascular & Aortic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PENPenumbra, Inc.	13.73B	350.49	973.58	12.86%	12.3%	12.07%	1.07%	0.19
NVNOenVVeno Medical Corporation	6.35M	0.31	-0.25			-74.59%		0.03
NUWENuwellis, Inc.	2.14M	2.37	-0.30	-1.4%	-202.83%	-423.93%		0.08
NSPRInspireMD, Inc.	67.79M	1.60	-2.11	12.96%	-5.94%	-72.06%		0.06
OMOutset Medical, Inc.	95.49M	5.26	-2.14	-12.8%	-73.12%	-61.67%		7.53
SRDXSurmodics, Inc.	614.51M	42.98	-52.41	-4.91%	-14.59%	-15.84%		0.28
AORTArtivion, Inc.	2.05B	43.29	-135.28	9.75%	-2.16%	-2.08%	0.54%	1.31

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	785.91K	422.11K	186.55K	31.24K	0	0	0	0	0
Revenue Growth %	-1%	-	-0.46%	-0.56%	-0.83%	-1%	-	-	-	-
Cost of Goods Sold+	125.42K	961.47K	558.87K	0	0	383.97K	452.91K	525K	546K	528K
COGS % of Revenue	-	1.22%	1.32%	-	-	-	-	-	-	-
Gross Profit+	-125.42K	-175.56K	-136.76K	0	0	-383.97K	-452.91K	-525K	-546K	-528K
Gross Margin %	-	-0.22%	-0.32%	-	-	-	-	-	-	-
Gross Profit Growth %	-3.19%	-0.4%	0.22%	1%	-	-	-0.18%	-0.16%	-0.04%	0.03%
Operating Expenses+	1.16M	4.48M	5.97M	7.59M	6.72M	8.75M	16.44M	24.41M	24.69M	23.3M
OpEx % of Revenue	-	5.7%	14.13%	40.68%	215.12%	-	-	-	-	-
Selling, General & Admin	1.16M	4.48M	5.32M	6.35M	4.51M	4.5M	10.71M	14.49M	11.11M	11.05M
SG&A % of Revenue	-	5.7%	12.6%	34.04%	144.51%	-	-	-	-	-
Research & Development	0	0	649.74K	1.24M	2.21M	4.25M	5.73M	9.91M	13.58M	12.25M
R&D % of Revenue	-	-	1.54%	6.64%	70.61%	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-1.29M	-4.66M	-6.1M	-7.54M	-7.09M	-9.14M	-16.89M	-24.93M	-25.24M	-23.83M
Operating Margin %	-	-5.93%	-14.46%	-40.39%	-226.82%	-	-	-	-	-
Operating Income Growth %	-0.35%	-2.61%	-0.31%	-0.23%	0.06%	-0.29%	-0.85%	-0.48%	-0.01%	0.06%
EBITDA+	-1.16M	-4.51M	-5.96M	-7.4M	-6.69M	-8.75M	-16.44M	-24.41M	-24.69M	-23.3M
EBITDA Margin %	-	-5.74%	-14.13%	-39.68%	-214.12%	-	-	-	-	-
EBITDA Growth %	-0.42%	-2.87%	-0.32%	-0.24%	0.1%	-0.31%	-0.88%	-0.48%	-0.01%	0.06%
D&A (Non-Cash Add-back)	125.42K	151.17K	139.21K	133.42K	396.67K	383.97K	452.91K	525K	546K	528K
EBIT	-1.29M	-5.53M	-5.87M	-6.18M	-7.62M	-9.14M	-16.53M	-24.67M	-23.52M	-21.82M
Net Interest Income+	-88.52K	-57.89K	-1.92M	-6.86M	49.91K	3.74K	18.71K	161K	180K	389K
Interest Income	0	0	0	0	50.85K	3.74K	18.71K	161K	180K	389K
Interest Expense	88.52K	57.89K	1.92M	6.86M	933	0	0	0	0	0
Other Income/Expense	-88.35K	-929.08K	-1.69M	-5.51M	-538.91K	-360	364.68K	263K	1.72M	2.01M
Pretax Income+	-1.38M	-5.59M	-7.79M	-13.04M	-7.63M	-9.14M	-16.53M	-24.67M	-23.52M	-21.82M
Pretax Margin %	-	-7.11%	-18.46%	-69.91%	-244.07%	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1.16%	1.05%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.6M	-5.89M	-7.79M	-13.04M	-7.63M	-9.14M	-16.53M	-24.67M	-23.52M	-21.82M
Net Margin %	-	-7.49%	-18.46%	-69.91%	-244.07%	-	-	-	-	-
Net Income Growth %	-0.15%	-2.67%	-0.32%	-0.67%	0.42%	-0.2%	-0.81%	-0.49%	0.05%	0.07%
Net Income (Continuing)	-1.38M	-5.59M	-7.79M	-13.04M	-7.63M	-9.14M	-16.53M	-24.67M	-23.52M	-21.82M
Discontinued Operations	-225.81K	2.2M	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.66	-7.72	-20.10	-34.83	-12.10	-7.54	-1.90	-2.20	-1.91	-1.27
EPS Growth %	0.14%	-1.11%	-1.6%	-0.73%	0.65%	0.38%	0.75%	-0.16%	0.13%	0.34%
EPS (Basic)	-3.66	-7.72	-20.10	-34.83	-12.10	-7.54	-1.90	-2.20	-1.91	-1.27
Diluted Shares Outstanding	438.72K	438.72K	387.69K	374.5K	630.42K	1.29M	8.68M	11.23M	12.3M	17.14M
Basic Shares Outstanding	438.72K	438.72K	387.69K	374.5K	630.42K	1.29M	8.68M	11.23M	12.3M	17.14M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.78M	393.22K	170.41K	2.84M	1.42M	9.57M	55.04M	39.44M	46.92M	43.73M
Cash & Short-Term Investments	1.59M	56.51K	77.69K	2.74M	1.31M	9.33M	54.73M	39.04M	46.41M	43.15M
Cash Only	1.59M	56.51K	77.69K	2.74M	1.31M	9.33M	54.73M	4.55M	3.62M	1.75M
Short-Term Investments	0	0	0	0	0	0	0	34.49M	42.79M	41.4M
Accounts Receivable	0	199.75K	35.18K	32.02K	0	0	0	0	0	0
Days Sales Outstanding	-	92.77	30.42	62.65	-	-	-	-	-	-
Inventory	0	90.91K	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	34.51	-	-	-	-	-	-	-	-
Other Current Assets	183.97K	56.05K	57.54K	64.31K	116.65K	234.47K	312.35K	392K	511K	581K
Total Non-Current Assets+	1.09M	1.39M	2.04M	722.46K	2.01M	968.78K	2.66M	2.23M	1.71M	1.22M
Property, Plant & Equipment	64.66K	28.81K	23.84K	26.15K	1.17M	938.94K	2.6M	2.19M	1.68M	1.19M
Fixed Asset Turnover	-	27.28x	17.70x	7.13x	0.03x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	899.41K	1.23M	1.11M	666.47K	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	810.05K	0	0	0	0	0
Other Non-Current Assets	126.11K	128.12K	911.22K	29.84K	29.84K	29.84K	54.49K	31K	31K	31K
Total Assets+	2.87M	1.78M	2.21M	3.56M	3.43M	10.54M	57.7M	41.66M	48.63M	44.95M
Asset Turnover	-	0.44x	0.19x	0.05x	0.01x	-	-	-	-	-
Asset Growth %	0.8%	-0.38%	0.24%	0.61%	-0.04%	2.07%	4.48%	-0.28%	0.17%	-0.08%
Total Current Liabilities+	4.66M	1.52M	4.99M	1.49M	1.88M	3.19M	1.58M	1.53M	1.37M	2.1M
Accounts Payable	618.28K	541.96K	1.45M	1.08M	1.22M	1.39M	560.08K	648K	0	1.01M
Days Payables Outstanding	1.8K	205.74	947.81	-	-	1.32K	451.37	450.51	-	695.44
Short-Term Debt	1.83M	632.77K	2.62M	0	288.69K	626.9K	291.1K	314K	338K	364K
Deferred Revenue (Current)	0	11.95K	4.98K	0	33K	33K	0	0	0	0
Other Current Liabilities	2.09M	34.45K	363.06K	124.32K	181.58K	662.17K	204.35K	177K	555K	121K
Current Ratio	0.38x	0.26x	0.03x	1.90x	0.76x	3.00x	34.83x	25.78x	34.23x	20.88x
Quick Ratio	0.38x	0.20x	0.03x	1.90x	0.76x	3.00x	34.83x	25.78x	34.23x	20.88x
Cash Conversion Cycle	-	-78.46	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	551.35K	3.18M	33K	567.95K	253.75K	1.71M	1.4M	1.06M	700K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	567.95K	253.75K	1.71M	1.4M	1.06M	700K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	3.94M	-103.4K	0	0	0	0	0	0	0
Total Liabilities	4.66M	6M	13.35M	1.52M	2.44M	3.44M	3.29M	2.93M	2.44M	2.79M
Total Debt+	1.83M	632.77K	2.62M	0	856.63K	880.65K	2.01M	1.72M	1.4M	1.06M
Net Debt	245.7K	576.26K	2.54M	-2.74M	-450.6K	-8.45M	-52.72M	-2.84M	-2.22M	-690K
Debt / Equity	-	-	-	-	0.87x	0.12x	0.04x	0.04x	0.03x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-14.57x	-80.48x	-3.18x	-1.10x	-7595.38x	-	-	-	-	-
Total Equity+	-1.78M	-4.22M	-11.13M	2.04M	989.94K	7.1M	54.4M	38.73M	46.2M	42.16M
Equity Growth %	0.11%	-1.37%	-1.64%	1.18%	-0.51%	6.17%	6.66%	-0.29%	0.19%	-0.09%
Book Value per Share	-4.06	-9.62	-28.71	5.44	1.57	5.50	6.27	3.45	3.76	2.46
Total Shareholders' Equity	-1.78M	-4.22M	-11.13M	2.04M	989.94K	7.1M	54.4M	38.73M	46.2M	42.16M
Common Stock	120	122	61	117	179	25	95	0	0	0
Retained Earnings	-24.34M	-27.73M	-35.52M	-48.56M	-56.19M	-65.32M	-81.85M	-106.52M	-130.04M	-151.85M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-3.94M	-5.17M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.02M	-3.08M	-4.2M	-6.36M	-5.9M	-7.68M	-11.85M	-15.62M	-18.86M	-16.84M
Operating CF Margin %	-	-3.92%	-9.96%	-34.07%	-188.73%	-	-	-	-	-
Operating CF Growth %	-16589.06%	-0.53%	-0.36%	-0.51%	0.07%	-0.3%	-0.54%	-0.32%	-0.21%	0.11%
Net Income	-1.6M	-3.39M	-7.79M	-13.04M	-7.63M	-9.14M	-16.53M	-24.67M	-23.52M	-21.82M
Depreciation & Amortization	125.42K	151.17K	139.21K	133.42K	396.67K	383.97K	452.91K	525K	546K	528K
Stock-Based Compensation	0	1.51M	878.4K	1.92M	941.96K	0	6M	8.99M	5.2M	4.14M
Deferred Taxes	0	871.18K	-231.41K	-1.35M	588.82K	0	-312.7K	0	0	0
Other Non-Cash Items	-177	-2.5M	1.71M	6.56M	-265.24K	697.21K	-312.43K	-339K	-468K	22K
Working Capital Changes	-540.7K	269.31K	1.09M	-578.4K	66.79K	377.1K	-1.14M	-130K	-616K	290K
Change in Receivables	25.24K	309K	-11.68K	3.16K	32.02K	0	0	0	0	0
Change in Inventory	171.9K	-213.18K	90.91K	-217.04K	0	0	0	0	0	0
Change in Payables	-83.54K	-76.32K	545.38K	-294.12K	144.07K	169.17K	-832.7K	88K	-221K	0
Cash from Investing+	-77.62K	-705.27K	165.31K	-12.42K	-363.89K	-180.29K	-367.89K	-34.55M	-7.87M	1.33M
Capital Expenditures	-2.62K	-373.62K	-10.94K	-12.42K	-363.89K	-180.29K	-367.89K	-115K	-33K	-37K
CapEx % of Revenue	-	0.48%	0.03%	0.07%	11.65%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-75K	-331.65K	176.25K	0	0	0	0	-34.44K	0	0
Cash from Financing+	3.62M	2.26M	4.06M	9.03M	5.64M	15.07M	57.61M	0	25.79M	13.64M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	745.75K	100K	-209.96K	-706.6K	0	0	244.89K	0	0	46K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.02M	-3.46M	-4.21M	-6.37M	-6.26M	-7.86M	-12.21M	-15.73M	-18.89M	-16.88M
FCF Margin %	-	-4.4%	-9.98%	-34.14%	-200.37%	-	-	-	-	-
FCF Growth %	-22255.93%	-0.71%	-0.22%	-0.51%	0.02%	-0.26%	-0.55%	-0.29%	-0.2%	0.11%
FCF per Share	-4.61	-7.88	-10.87	-17.00	-9.93	-6.08	-1.41	-1.40	-1.54	-0.98
FCF Conversion (FCF/Net Income)	1.26x	0.52x	0.54x	0.49x	0.77x	0.84x	0.72x	0.63x	0.80x	0.77x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-640.47%	-503.93%	-225.91%	-53.75%	-52.98%	-55.38%	-49.39%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-7763.98%	-99.54%	-47.4%	-41.82%
Gross Margin	-	-22.34%	-32.4%	-	-	-	-	-	-	-
Net Margin	-	-749.01%	-1845.83%	-6991.46%	-24406.74%	-	-	-	-	-
Debt / Equity	-	-	-	-	0.87x	0.12x	0.04x	0.04x	0.03x	0.03x
Interest Coverage	-14.57x	-80.48x	-3.18x	-1.10x	-7595.38x	-	-	-	-	-
FCF Conversion	1.26x	0.52x	0.54x	0.49x	0.77x	0.84x	0.72x	0.63x	0.80x	0.77x
Revenue Growth	-100%	-	-46.29%	-55.81%	-83.25%	-100%	-	-	-	-

Revenue by Segment

	2018	2019
Royalty Income	116.15K	31.24K
Royalty Income Growth	-	-73.10%
Contract Research - Related Party	70.4K	-
Contract Research - Related Party Growth	-	-

Frequently Asked Questions

Growth & Financials

enVVeno Medical Corporation (NVNO) grew revenue by 0.0% over the past year. Growth has been modest.

enVVeno Medical Corporation (NVNO) reported a net loss of $22.0M for fiscal year 2024.

Dividend & Returns

enVVeno Medical Corporation (NVNO) has a return on equity (ROE) of -49.4%. Negative ROE indicates the company is unprofitable.

enVVeno Medical Corporation (NVNO) had negative free cash flow of $17.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

enVVeno Medical Corporation (NVNO) 10-Year Financial Performance & Capital Metrics

NVNO • • Industrial / General

HealthcareMedical DevicesCardiovascular DevicesVascular & Aortic Devices

Revenue $0
EBITDA -$23M +5.6%
Net Income -$22M +7.2%
EPS (Diluted) -1.27 +33.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -49.39% +10.8%
ROIC -41.82% +11.8%
Debt/Equity 0.03 -16.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 39.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM21.58%

ROCE

10Y Avg-364.56%

5Y Avg-84.15%

3Y Avg-54.15%

Latest-52.87%

Peer Comparison

Vascular & Aortic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PENPenumbra, Inc.	13.73B	350.49	973.58	12.86%	12.3%	12.07%	1.07%	0.19
NVNOenVVeno Medical Corporation	6.35M	0.31	-0.25			-74.59%		0.03
NUWENuwellis, Inc.	2.14M	2.37	-0.30	-1.4%	-202.83%	-423.93%		0.08
NSPRInspireMD, Inc.	67.79M	1.60	-2.11	12.96%	-5.94%	-72.06%		0.06
OMOutset Medical, Inc.	95.49M	5.26	-2.14	-12.8%	-73.12%	-61.67%		7.53
SRDXSurmodics, Inc.	614.51M	42.98	-52.41	-4.91%	-14.59%	-15.84%		0.28
AORTArtivion, Inc.	2.05B	43.29	-135.28	9.75%	-2.16%	-2.08%	0.54%	1.31

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	785.91K	422.11K	186.55K	31.24K	0	0	0	0	0
Revenue Growth %	-1%	-	-0.46%	-0.56%	-0.83%	-1%	-	-	-	-
Cost of Goods Sold+	125.42K	961.47K	558.87K	0	0	383.97K	452.91K	525K	546K	528K
COGS % of Revenue	-	1.22%	1.32%	-	-	-	-	-	-	-
Gross Profit+	-125.42K	-175.56K	-136.76K	0	0	-383.97K	-452.91K	-525K	-546K	-528K
Gross Margin %	-	-0.22%	-0.32%	-	-	-	-	-	-	-
Gross Profit Growth %	-3.19%	-0.4%	0.22%	1%	-	-	-0.18%	-0.16%	-0.04%	0.03%
Operating Expenses+	1.16M	4.48M	5.97M	7.59M	6.72M	8.75M	16.44M	24.41M	24.69M	23.3M
OpEx % of Revenue	-	5.7%	14.13%	40.68%	215.12%	-	-	-	-	-
Selling, General & Admin	1.16M	4.48M	5.32M	6.35M	4.51M	4.5M	10.71M	14.49M	11.11M	11.05M
SG&A % of Revenue	-	5.7%	12.6%	34.04%	144.51%	-	-	-	-	-
Research & Development	0	0	649.74K	1.24M	2.21M	4.25M	5.73M	9.91M	13.58M	12.25M
R&D % of Revenue	-	-	1.54%	6.64%	70.61%	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-1.29M	-4.66M	-6.1M	-7.54M	-7.09M	-9.14M	-16.89M	-24.93M	-25.24M	-23.83M
Operating Margin %	-	-5.93%	-14.46%	-40.39%	-226.82%	-	-	-	-	-
Operating Income Growth %	-0.35%	-2.61%	-0.31%	-0.23%	0.06%	-0.29%	-0.85%	-0.48%	-0.01%	0.06%
EBITDA+	-1.16M	-4.51M	-5.96M	-7.4M	-6.69M	-8.75M	-16.44M	-24.41M	-24.69M	-23.3M
EBITDA Margin %	-	-5.74%	-14.13%	-39.68%	-214.12%	-	-	-	-	-
EBITDA Growth %	-0.42%	-2.87%	-0.32%	-0.24%	0.1%	-0.31%	-0.88%	-0.48%	-0.01%	0.06%
D&A (Non-Cash Add-back)	125.42K	151.17K	139.21K	133.42K	396.67K	383.97K	452.91K	525K	546K	528K
EBIT	-1.29M	-5.53M	-5.87M	-6.18M	-7.62M	-9.14M	-16.53M	-24.67M	-23.52M	-21.82M
Net Interest Income+	-88.52K	-57.89K	-1.92M	-6.86M	49.91K	3.74K	18.71K	161K	180K	389K
Interest Income	0	0	0	0	50.85K	3.74K	18.71K	161K	180K	389K
Interest Expense	88.52K	57.89K	1.92M	6.86M	933	0	0	0	0	0
Other Income/Expense	-88.35K	-929.08K	-1.69M	-5.51M	-538.91K	-360	364.68K	263K	1.72M	2.01M
Pretax Income+	-1.38M	-5.59M	-7.79M	-13.04M	-7.63M	-9.14M	-16.53M	-24.67M	-23.52M	-21.82M
Pretax Margin %	-	-7.11%	-18.46%	-69.91%	-244.07%	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1.16%	1.05%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.6M	-5.89M	-7.79M	-13.04M	-7.63M	-9.14M	-16.53M	-24.67M	-23.52M	-21.82M
Net Margin %	-	-7.49%	-18.46%	-69.91%	-244.07%	-	-	-	-	-
Net Income Growth %	-0.15%	-2.67%	-0.32%	-0.67%	0.42%	-0.2%	-0.81%	-0.49%	0.05%	0.07%
Net Income (Continuing)	-1.38M	-5.59M	-7.79M	-13.04M	-7.63M	-9.14M	-16.53M	-24.67M	-23.52M	-21.82M
Discontinued Operations	-225.81K	2.2M	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.66	-7.72	-20.10	-34.83	-12.10	-7.54	-1.90	-2.20	-1.91	-1.27
EPS Growth %	0.14%	-1.11%	-1.6%	-0.73%	0.65%	0.38%	0.75%	-0.16%	0.13%	0.34%
EPS (Basic)	-3.66	-7.72	-20.10	-34.83	-12.10	-7.54	-1.90	-2.20	-1.91	-1.27
Diluted Shares Outstanding	438.72K	438.72K	387.69K	374.5K	630.42K	1.29M	8.68M	11.23M	12.3M	17.14M
Basic Shares Outstanding	438.72K	438.72K	387.69K	374.5K	630.42K	1.29M	8.68M	11.23M	12.3M	17.14M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.78M	393.22K	170.41K	2.84M	1.42M	9.57M	55.04M	39.44M	46.92M	43.73M
Cash & Short-Term Investments	1.59M	56.51K	77.69K	2.74M	1.31M	9.33M	54.73M	39.04M	46.41M	43.15M
Cash Only	1.59M	56.51K	77.69K	2.74M	1.31M	9.33M	54.73M	4.55M	3.62M	1.75M
Short-Term Investments	0	0	0	0	0	0	0	34.49M	42.79M	41.4M
Accounts Receivable	0	199.75K	35.18K	32.02K	0	0	0	0	0	0
Days Sales Outstanding	-	92.77	30.42	62.65	-	-	-	-	-	-
Inventory	0	90.91K	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	34.51	-	-	-	-	-	-	-	-
Other Current Assets	183.97K	56.05K	57.54K	64.31K	116.65K	234.47K	312.35K	392K	511K	581K
Total Non-Current Assets+	1.09M	1.39M	2.04M	722.46K	2.01M	968.78K	2.66M	2.23M	1.71M	1.22M
Property, Plant & Equipment	64.66K	28.81K	23.84K	26.15K	1.17M	938.94K	2.6M	2.19M	1.68M	1.19M
Fixed Asset Turnover	-	27.28x	17.70x	7.13x	0.03x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	899.41K	1.23M	1.11M	666.47K	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	810.05K	0	0	0	0	0
Other Non-Current Assets	126.11K	128.12K	911.22K	29.84K	29.84K	29.84K	54.49K	31K	31K	31K
Total Assets+	2.87M	1.78M	2.21M	3.56M	3.43M	10.54M	57.7M	41.66M	48.63M	44.95M
Asset Turnover	-	0.44x	0.19x	0.05x	0.01x	-	-	-	-	-
Asset Growth %	0.8%	-0.38%	0.24%	0.61%	-0.04%	2.07%	4.48%	-0.28%	0.17%	-0.08%
Total Current Liabilities+	4.66M	1.52M	4.99M	1.49M	1.88M	3.19M	1.58M	1.53M	1.37M	2.1M
Accounts Payable	618.28K	541.96K	1.45M	1.08M	1.22M	1.39M	560.08K	648K	0	1.01M
Days Payables Outstanding	1.8K	205.74	947.81	-	-	1.32K	451.37	450.51	-	695.44
Short-Term Debt	1.83M	632.77K	2.62M	0	288.69K	626.9K	291.1K	314K	338K	364K
Deferred Revenue (Current)	0	11.95K	4.98K	0	33K	33K	0	0	0	0
Other Current Liabilities	2.09M	34.45K	363.06K	124.32K	181.58K	662.17K	204.35K	177K	555K	121K
Current Ratio	0.38x	0.26x	0.03x	1.90x	0.76x	3.00x	34.83x	25.78x	34.23x	20.88x
Quick Ratio	0.38x	0.20x	0.03x	1.90x	0.76x	3.00x	34.83x	25.78x	34.23x	20.88x
Cash Conversion Cycle	-	-78.46	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	551.35K	3.18M	33K	567.95K	253.75K	1.71M	1.4M	1.06M	700K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	567.95K	253.75K	1.71M	1.4M	1.06M	700K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	3.94M	-103.4K	0	0	0	0	0	0	0
Total Liabilities	4.66M	6M	13.35M	1.52M	2.44M	3.44M	3.29M	2.93M	2.44M	2.79M
Total Debt+	1.83M	632.77K	2.62M	0	856.63K	880.65K	2.01M	1.72M	1.4M	1.06M
Net Debt	245.7K	576.26K	2.54M	-2.74M	-450.6K	-8.45M	-52.72M	-2.84M	-2.22M	-690K
Debt / Equity	-	-	-	-	0.87x	0.12x	0.04x	0.04x	0.03x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-14.57x	-80.48x	-3.18x	-1.10x	-7595.38x	-	-	-	-	-
Total Equity+	-1.78M	-4.22M	-11.13M	2.04M	989.94K	7.1M	54.4M	38.73M	46.2M	42.16M
Equity Growth %	0.11%	-1.37%	-1.64%	1.18%	-0.51%	6.17%	6.66%	-0.29%	0.19%	-0.09%
Book Value per Share	-4.06	-9.62	-28.71	5.44	1.57	5.50	6.27	3.45	3.76	2.46
Total Shareholders' Equity	-1.78M	-4.22M	-11.13M	2.04M	989.94K	7.1M	54.4M	38.73M	46.2M	42.16M
Common Stock	120	122	61	117	179	25	95	0	0	0
Retained Earnings	-24.34M	-27.73M	-35.52M	-48.56M	-56.19M	-65.32M	-81.85M	-106.52M	-130.04M	-151.85M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-3.94M	-5.17M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.02M	-3.08M	-4.2M	-6.36M	-5.9M	-7.68M	-11.85M	-15.62M	-18.86M	-16.84M
Operating CF Margin %	-	-3.92%	-9.96%	-34.07%	-188.73%	-	-	-	-	-
Operating CF Growth %	-16589.06%	-0.53%	-0.36%	-0.51%	0.07%	-0.3%	-0.54%	-0.32%	-0.21%	0.11%
Net Income	-1.6M	-3.39M	-7.79M	-13.04M	-7.63M	-9.14M	-16.53M	-24.67M	-23.52M	-21.82M
Depreciation & Amortization	125.42K	151.17K	139.21K	133.42K	396.67K	383.97K	452.91K	525K	546K	528K
Stock-Based Compensation	0	1.51M	878.4K	1.92M	941.96K	0	6M	8.99M	5.2M	4.14M
Deferred Taxes	0	871.18K	-231.41K	-1.35M	588.82K	0	-312.7K	0	0	0
Other Non-Cash Items	-177	-2.5M	1.71M	6.56M	-265.24K	697.21K	-312.43K	-339K	-468K	22K
Working Capital Changes	-540.7K	269.31K	1.09M	-578.4K	66.79K	377.1K	-1.14M	-130K	-616K	290K
Change in Receivables	25.24K	309K	-11.68K	3.16K	32.02K	0	0	0	0	0
Change in Inventory	171.9K	-213.18K	90.91K	-217.04K	0	0	0	0	0	0
Change in Payables	-83.54K	-76.32K	545.38K	-294.12K	144.07K	169.17K	-832.7K	88K	-221K	0
Cash from Investing+	-77.62K	-705.27K	165.31K	-12.42K	-363.89K	-180.29K	-367.89K	-34.55M	-7.87M	1.33M
Capital Expenditures	-2.62K	-373.62K	-10.94K	-12.42K	-363.89K	-180.29K	-367.89K	-115K	-33K	-37K
CapEx % of Revenue	-	0.48%	0.03%	0.07%	11.65%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-75K	-331.65K	176.25K	0	0	0	0	-34.44K	0	0
Cash from Financing+	3.62M	2.26M	4.06M	9.03M	5.64M	15.07M	57.61M	0	25.79M	13.64M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	745.75K	100K	-209.96K	-706.6K	0	0	244.89K	0	0	46K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.02M	-3.46M	-4.21M	-6.37M	-6.26M	-7.86M	-12.21M	-15.73M	-18.89M	-16.88M
FCF Margin %	-	-4.4%	-9.98%	-34.14%	-200.37%	-	-	-	-	-
FCF Growth %	-22255.93%	-0.71%	-0.22%	-0.51%	0.02%	-0.26%	-0.55%	-0.29%	-0.2%	0.11%
FCF per Share	-4.61	-7.88	-10.87	-17.00	-9.93	-6.08	-1.41	-1.40	-1.54	-0.98
FCF Conversion (FCF/Net Income)	1.26x	0.52x	0.54x	0.49x	0.77x	0.84x	0.72x	0.63x	0.80x	0.77x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-640.47%	-503.93%	-225.91%	-53.75%	-52.98%	-55.38%	-49.39%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-7763.98%	-99.54%	-47.4%	-41.82%
Gross Margin	-	-22.34%	-32.4%	-	-	-	-	-	-	-
Net Margin	-	-749.01%	-1845.83%	-6991.46%	-24406.74%	-	-	-	-	-
Debt / Equity	-	-	-	-	0.87x	0.12x	0.04x	0.04x	0.03x	0.03x
Interest Coverage	-14.57x	-80.48x	-3.18x	-1.10x	-7595.38x	-	-	-	-	-
FCF Conversion	1.26x	0.52x	0.54x	0.49x	0.77x	0.84x	0.72x	0.63x	0.80x	0.77x
Revenue Growth	-100%	-	-46.29%	-55.81%	-83.25%	-100%	-	-	-	-

Revenue by Segment

	2018	2019
Royalty Income	116.15K	31.24K
Royalty Income Growth	-	-73.10%
Contract Research - Related Party	70.4K	-
Contract Research - Related Party Growth	-	-

Frequently Asked Questions

Growth & Financials

enVVeno Medical Corporation (NVNO) grew revenue by 0.0% over the past year. Growth has been modest.

enVVeno Medical Corporation (NVNO) reported a net loss of $22.0M for fiscal year 2024.

Dividend & Returns

enVVeno Medical Corporation (NVNO) has a return on equity (ROE) of -49.4%. Negative ROE indicates the company is unprofitable.

enVVeno Medical Corporation (NVNO) had negative free cash flow of $17.2M in fiscal year 2024, likely due to heavy capital investments.